melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-16. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
== Early life and education == Lucy Letby was born on 4 January 1990 in Hereford, the only child of a furniture salesman and an accounts clerk. She attended St. James' Church of England primary school, Aylestone School and Hereford Sixth Form College. According to a friend interviewed by the BBC, she had long expressed an interest in neonatal nursing. Letby studied child nursing at the University of Chester, completing clinical placements at Liverpool Women's Hospital and the Countess of Chester Hospital. During her final year she failed an assessed placement but passed a subsequent retrieval placement after requesting a different assessor. One of her assessors later told the 2024 statutory inquiry that she had considered Letby inexperienced and lacking confidence in some clinical areas. Letby graduated with a Bachelor of Science in Nursing with a speciality in child nursing in September 2011 and completed a further placement at Liverpool Women's Hospital the following year.
=== Synaptogenesis === BDNF also enhances synaptogenesis. Synaptogenesis is dependent upon the assembly of new synapses and the disassembly of old synapses by β-adducin. Adducins are membrane-skeletal proteins that cap the growing ends of actin filaments and promote their association with spectrin, another cytoskeletal protein, to create stable and integrated cytoskeletal networks. Actins have a variety of roles in synaptic functioning. In pre-synaptic neurons, actins are involved in synaptic vesicle recruitment and vesicle recovery following neurotransmitter release. In post-synaptic neurons they can influence dendritic spine formation and retraction as well as AMPA receptor insertion and removal. At their C-terminus, adducins possess a myristoylated alanine-rich C kinase substrate (MARCKS) domain which regulates their capping activity. BDNF can reduce capping activities by upregulating PKC, which can bind to the adducing MRCKS domain, inhibit capping activity, and promote synaptogenesis through dendritic spine growth and disassembly and other activities.
== External links == agouti+protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Vitamin B12: Low serum B12 level is a common finding in diabetics especially those taking Metformin or in advanced age. Vitamin B12 deficiency has been linked to two diabetic complications; atherosclerosis and diabetic neuropathy.
Sources: en.wikipedia.org
== Lawsuits == In November 2016, three men filed a class-action lawsuit against Chipotle alleging that a burrito was listed as containing only 300 calories, when in fact it contained more. They are seeking "unspecified damages and for an injunction against the company to prevent it from posting what it calls misleading information on its food". In January 2020, the company was fined $1.3 million by the state of Massachusetts for 13,000 child labor violations.
cells derived from Fyn-/- mice (as well as cells derived from Fyn, Src, Yes, Fyn triple knockout mice (SYF)); a kinase-inactive, dominant negative mutant form of Fyn (K299M); pharmacologic inhibitors of Src family kinases, such as PP2; note that PP2 also inhibits other tyrosine protein kinases such as Abl, PDGFR and c-Kit. Using these tools, a requirement for Fyn has been shown for the following signaling pathways: T and B cell receptor signaling, integrin-mediated signaling, growth factor and cytokine receptor signaling, platelet activation, ion channel function, cell adhesion, axon guidance, fertilization, entry into mitosis, and differentiation of natural killer cells, oligodendrocytes and keratinocytes. Fyn also has an important role to play in TLR-mediated immune responses from T cells.
"The discovery of radium". Lateral Science. UK. 8 July 2012. Archived from the original on 9 March 2016. Retrieved 13 May 2017. Radium water bath in Oklahoma. markwshead.com (photographic images). "Radium, radioactive". NLM Hazardous Substances Databank. U.S. National Institutes of Health. Archived from the original on 1 July 2018. "Annotated bibliography for radium". Alsos Digital Library for Nuclear Issues. Lexington, VA: Washington and Lee University. Archived from the original on 25 June 2019. "Radium". The Periodic Table of Videos. University of Nottingham.
== Clinical significance == Current scientific evidence indicates that both up- and down-regulation of the expression of proprotein convertases are part of the multiple changes occurring in gynecological tumors. PCs activate crucial substrates implicated in the progression of gynecological cancers, including adhesion molecules, metalloproteinases, and viral proteins. Experimental evidences suggest that careful targeting of PCs in gynecological cancer may represent a feasible strategy to deter tumor progression. Variants of PCSK9 can reduce or increase circulating cholesterol. Furin plays a role in the activation of several different virus proteins, and inhibitors of furin have been explored as antiviral agents.
In late 1918, Poles hoping for a sovereign Poland started serious preparations for an uprising after Wilhelm II's abdication on 9 November 1918, which marked the end of the German Empire. The monarchy was replaced by the Weimar Republic. The uprising broke out on 27 December 1918 in Poznań, after a patriotic speech by Ignacy Paderewski, the famous pianist, who would become the Polish prime minister in 1919, with 2,000 men serving in the Guard and Security Service rising up in the city. The insurrectionist forces consisted of members of the Polish Military Organization, who formed the Straż Obywatelska (Citizen's Guard), later renamed as Straż Ludowa (People's Guard), which included many volunteers, who were mainly veterans of World War I. The first contingent to reach the Bazar Hotel, from where the uprising was initiated, was a 100-strong force from wildecka kompania Straży Ludowej (Wilda's People's Guard) led by Antoni Wysocki. The ruling body was the Naczelna Rada Ludowa (Supreme People's Council). Initially, the members of the council, including Captain Stanisław Taczak and General Józef Dowbor-Muśnicki were against the uprising, but they changed their minds in support of the insurrection on 9 January 1919. The timing was advantageous for the insurrectionists since between late 1918 and early 1919, internal conflict had weakened Germany, and many of its soldiers and sailors engaged in mutinous actions against the state. Demoralized by the signing of the armistice on 11 November 1918, the new German government was further embroiled in subduing the German Revolution.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.